In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...

IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...

Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...

MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.90 per share a year ago. These ...

Additionally, thymic IgM B cells reactive to adducts were more likely to recognize ... and filtered through a 40 μm cell strainer (BD Biosciences). Thymocyte cell suspensions were then cryopreserved ...

The US presidential election is just over a week away. Market (^DJI, ^IXIC, ^GSPC) volatility linked to electoral uncertainty has emerged as a key concern for investors. However, Federated Hermes ...

The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...